Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model

Targeted Silencing of Anthrax Toxin Receptors Protects against Anthrax Toxins

“…However, using siRNA as a therapy against disease offers several advantages over the use of antibody-based therapies. Beyond cost effectiveness and the high level of specificity of using siRNA, we can also circumvent unwanted immune responses associated with use of antibody therapies (38,39). Furthermore, several siRNAs can easily be designed, synthesized, and characterized to maximize specificity and reduce undesirable nonspecific effects for each target.…”

Galectin-9 ameliorates herpes simplex virus-induced inflammation through apoptosis

“…TNF␣ overexpression has been implicated in acute and chronic inflammatory diseases, such as septic shock, bowel disease, Crohn's disease, rheumatoid arthritis, atopic dermatitis, psoriasis, and BD (Edwards 2004). Choi et al (2008) reported the improvement of inflammatory symptoms after TNF␣ inhibition through TNF␣ siRNA treatment in BD-like mice. The Gal-9-treated group had a significantly lower serum level of TNF␣ than the control group.…”

Synthesized pyridine compound derivatives decreased TNF alpha and adhesion molecules and ameliorated HSV-induced inflammation in a mouse model

“…TNFα and adhesion molecules have been shown to be up-regulated in Behcet's disease patients (Sayinalp et al, 1996;Kose et al, 2008). In addition, downregulation of TNFα using anti-TNFα antibody (Infliximab) was found to suppress various Behcet's disease symptoms including sight-threatening panuveitis (Sfikakis et al, 2001) and intestinal ulcers (Ju et al, 2007) in patients and mice (Choi et al, 2008). Another TNFα blocker, Etanercept, is also known to be an effective therapeutic agent for Behcet's disease patients and mice (Cantarini et al, 2009;Choi et al, 2008).…”

“…In addition, downregulation of TNFα using anti-TNFα antibody (Infliximab) was found to suppress various Behcet's disease symptoms including sight-threatening panuveitis (Sfikakis et al, 2001) and intestinal ulcers (Ju et al, 2007) in patients and mice (Choi et al, 2008). Another TNFα blocker, Etanercept, is also known to be an effective therapeutic agent for Behcet's disease patients and mice (Cantarini et al, 2009;Choi et al, 2008). All TNFα blockers are administered by injection; however, if orally administered TNFα blockers were available it would increase comfort for the patients.…”